# IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

> **NCT05780307** · PHASE1 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Breast Cancer
- Squamous Cell Cancer of Head and Neck
- Colorectal Cancer

## Interventions

- **DRUG:** IMM2520

## Key facts

- **NCT ID:** NCT05780307
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-23
- **Primary completion:** 2024-03-10
- **Final completion:** 2025-10-26
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780307, "IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05780307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*